NEW DELHI – India is taking a series of steps to power its biopharmaceutical industry that could lead to more investment, better infrastructure for drug development and a visible reduction in red tape. One of the more significant such steps is the development of a series of biotech and pharmaceutical industry clusters that could help speed up drug discovery and development.
NEW DELHI – India is taking a series of steps to power its biopharmaceutical industry that could lead to more investment, better infrastructure for drug development and a visible reduction in red tape. One of the more significant such steps is the development of a series of biotech and pharmaceutical industry clusters that could help speed up drug discovery and development.
NEW DELHI – In a test of India's law requiring sponsors of patented drugs to manufacture sufficient quantities in country, Cipla Ltd.'s challenge of Novartis AG's Indian patent for its chronic obstructive pulmonary disorder (COPD) drug Onbrez is raising questions about access, price and the correct way to contest a pharmaceutical patent.
HYDERABAD, India – A slew of measures to cut down the approval times for clinical trials, streamline regulatory guidelines and strengthen safety is helping India regain some traction as a site for trials – traction lost in the years through 2013.
NEW DELHI – In a test of India's law requiring sponsors of patented drugs to manufacture sufficient quantities in country, Cipla Ltd.'s challenge of Novartis AG's Indian patent for its chronic obstructive pulmonary disorder (COPD) drug Onbrez is raising questions about access, price and the correct way to contest a pharmaceutical patent.
HYDERABAD, India – A slew of measures to cut down the approval times for clinical trials, streamline regulatory guidelines and strengthen safety is helping India regain some traction as a site for trials – traction lost in the years through 2013.
HYDERABAD, India – If it can overcome some significant hurdles, India could emerge as a major developer of biosimilars in the coming years, said industry players speaking at the largest annual meeting of biotech companies here.
HYDERABAD, India – India may have a proven track record developing generics, but it is limping far behind other countries in the discovery and development of new drugs, areas which call for entirely new skill sets and investments.
HYDERABAD, India – If it can overcome some significant hurdles, India could emerge as a major developer of biosimilars in the coming years, said industry players speaking at the largest annual meeting of biotech companies here.
